Clinical Importance of Optimal Medical Therapy on the Clinical Outcomes of Patients with Acute Myocardial Infarction after Percutaneous Coronary Intervention

Figures

• 

  Figure 1.. Study flowchart showing patient selection. ACS: acute coronary syndrome, AMI: acute myocardial infarction, OMT: optimal medical therapy, PCI: percutaneous coronary intervention

• 

  Figure 2.. A Kaplan-Meier analysis of the cumulative incidence of the primary outcome measure, all-cause death, and secondary outcome measure between the OMT and non-OMT groups. (a) A Kaplan-Meier analysis for the primary outcome measure between the OMT and non-OMT groups. (b) A Kaplan-Meier analysis for all-cause death between the OMT and non-OMT groups. (c) A Kaplan-Meier analysis for the secondary bleeding outcome measure between the OMT and non-OMT groups. (d) A Kaplan-Meier analysis for the secondary ischemic outcome measure between the OMT and non-OMT groups. BARC: Bleeding Academic Research Consortium, HF: heart failure, MACE: major adverse cardiovascular event, MI: myocardial infarction, OMT: optimal medical therapy

• 

  Figure 3.. A Kaplan-Meier analysis for the persistent discontinuation of DAPT between the OMT and non-OMT groups. DAPT: dual antiplatelet therapy, OMT: optimal medical therapy

• 

  Figure 4.. A Kaplan-Meier analysis of the cumulative incidence of the primary outcome measure, all-cause death, and secondary outcome measure between the OMT and non-OMT groups after PSM. (a) A Kaplan-Meier analysis for the primary outcome measure between the OMT and non-OMT groups after PSM. (b) A Kaplan-Meier analysis for all-cause death between the OMT and non-OMT groups after PSM. (c) A Kaplan-Meier analysis for the secondary bleeding outcome measure between the OMT and non-OMT groups after PSM. (d) A Kaplan-Meier analysis for the secondary ischemic outcome measure between the OMT and non-OMT groups after PSM. BARC: Bleeding Academic Research Consortium, HF: heart failure, MACE: major adverse cardiovascular event, MI: myocardial infarction, OMT: optimal medical therapy, PSM: propensity score matching

• 

  Figure 5.. A Kaplan-Meier analysis of the primary outcome measure stratified by OMT score: low (0-2), intermediate (3, 4), and high (5, 6). HF: heart failure, MACE: major adverse cardiovascular event, MI: myocardial infarction, OMT: optimal medical therapy

• 

  Figure 6.. A Kaplan-Meier analysis of the cumulative incidence of the primary outcome measure among the four groups: older patients (≥75 years old) without OMT, older patients (≥75 years old) with OMT, non-older patients (<75 years old) without OMT, and non-older patients (<75 years old) with OMT. HF: heart failure, MACE: major adverse cardiovascular event, MI: myocardial infarction, OMT: optimal medical therapy

• 

  Figure 7.. A multivariate analysis using Cox proportional hazards regression models for the primary outcome measure, incorporating OMT and older age (≥75 years old). The Forrest plot shows the HR and 95% CI compared to non-older patients (<75 years old) with OMT. No significant interaction was observed between OMT and older age (p value=0.416) or between OMT and STEMI/NSTEMI (p value=0.383). CI: confidence interval, OMT: optimal medical therapy, HR: hazard ratio, STEMI: ST-segment elevation myocardial infarction, NSTEMI: Non-ST-segment elevation myocardial infarction